J. Andrew Cittadine's most recent trade in Monopar Therapeutics Inc was a trade of 1,791 Common Stock done . Disclosure was reported to the exchange on March 31, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 1,791 | 42,729 (0%) | 0% | - | Common Stock | |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 1,791 | 49,864 | - | - | Restricted Stock Units | |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.41 per share. | 31 Mar 2025 | 744 | 41,985 (0%) | 0% | 36.4 | 27,089 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 43,445 | 43,445 | - | - | Stock Options | |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 40,581 | 51,655 | - | - | Restricted Stock Units | |
Monopar Therapeutics Inc | J. Andrew Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 1,790 | 11,074 | - | - | Restricted Stock Units | |
Monopar Therapeutics Inc | Cittadine J. Andrew | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 1,790 | 41,659 (0%) | 0% | - | Common Stock | |
Monopar Therapeutics Inc | Cittadine J. Andrew | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.00 per share. | 31 Dec 2024 | 721 | 40,938 (0%) | 0% | 22 | 15,862 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2024 | 1,791 | 40,404 (0%) | 0% | - | Common Stock | |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2024 | 1,791 | 12,864 | - | - | Restricted Stock Units | |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.74 per share. | 30 Sep 2024 | 535 | 39,869 (0%) | 0% | 6.7 | 3,606 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 8,952 | 73,271 | - | - | Restricted Stock Units | |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 8,952 | 195,084 (1%) | 0% | - | Common Stock | |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.73 per share. | 30 Jun 2024 | 2,019 | 193,065 (1%) | 0% | 0.7 | 1,476 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.74 per share. | 18 Jun 2024 | 20,508 | 186,132 (1%) | 0% | 0.7 | 15,254 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.86 per share. | 18 Jun 2024 | 12,000 | 165,624 (1%) | 0% | 0.9 | 10,320 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.90 per share. | 13 Jun 2024 | 12,000 | 153,624 (1%) | 0% | 0.9 | 10,799 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.93 per share. | 13 Jun 2024 | 12,000 | 141,624 (1%) | 0% | 0.9 | 11,176 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.91 per share. | 13 Jun 2024 | 12,000 | 129,624 (1%) | 0% | 0.9 | 10,920 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.76 per share. | 03 Jun 2024 | 12,000 | 105,624 (0%) | 0% | 0.8 | 9,120 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.78 per share. | 03 Jun 2024 | 12,000 | 117,624 (1%) | 0% | 0.8 | 9,360 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 29 May 2024 | 12,000 | 93,624 (0%) | 0% | 0.6 | 7,732 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 29 May 2024 | 12,000 | 69,624 (0%) | 0% | 0.6 | 7,643 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 29 May 2024 | 12,000 | 81,624 (0%) | 0% | 0.6 | 7,676 | Common Stock |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 25,000 | 25,000 | - | - | Stock Options | |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 8,952 | 82,223 | - | - | Restricted Stock Units | |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 8,952 | 60,722 (0%) | 0% | - | Common Stock | |
Monopar Therapeutics Inc | Andrew J. Cittadine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.68 per share. | 31 Mar 2024 | 3,098 | 57,624 (0%) | 0% | 0.7 | 2,110 | Common Stock |